IP Library Granted Patent US 10,933,060
Granted Patent B1
US 10,933,060 · App. 16/904,104 · Granted Mar 2, 2021

Pharmaceutical compositions and methods of using the same

Inventors: Jeffrey M. Moshal (Allentown, PA); Michael Libman (Allentown, PA)
Assignee: GENUS LIFESCIENCES INC.
A61K31/46A61B1/233A61B1/267A61K9/0014A61K9/0019A61K9/0043A61K9/08A61K9/7007A61K31/573A61K45/06A61K47/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,933,060
App. No.
16/904,104
Granted
Mar 2, 2021
Kind
B1
Abstract

Novel pharmaceutical compositions including cocaine hydrochloride and methods of treating patients using those pharmaceutical compositions are described.

Claims (12)

1. A method for induction of local anesthesia prior to performing a medical procedure on, through, or adjacent to a mucous membrane of a nasal cavity of a patient comprising: soaking four absorbent articles with an aqueous solution comprising, by weight, about 36 mg/mL to about 44 mg/mL of cocaine hydrochloride, 1.2 mg/mL to 1.4 mg/mL citric acid, 0.7 mg/mL to 1.3 mg/mL sodium benzoate, and water; and contacting the absorbent articles with the mucous membrane in a nasal cavity of the patient for up to about 20 minutes to reduce sensation in a body region of the patient; provided that the method results in an absorptivity factor for cocaine in the patient ranging from about 0.25 h −1 to about 1.0 h −1 .

2. The method of claim 1 , wherein the absorbent articles comprise pledgets.

3. The method of claim 2 , wherein the pledgets comprise cottonoid pledgets.

4. The method of claim 1 , wherein each pledget is removed from the nasal cavity and retains between about 70% and about 80% of the cocaine hydrochloride.

5. The method of claim 1 , wherein the medical procedure performed is selected from the group consisting of a nasal endoscopy, a nasal laryngoscopy, a nasopharyngeal laryngoscopy, and a nasal debridement.

6. The method of claim 5 , wherein the procedure is a nasal endoscopy.

7. The method of claim 5 , wherein the procedure is a nasal laryngoscopy.

8. The method of claim 5 , wherein the procedure is a nasopharyngeal laryngoscopy.

9. The method of claim 5 wherein the procedure is a nasal debridement.

10. The method of claim 1 , wherein the method results in a T max ranging from about 0.02 hours to about 1.00 hours.

11. The method of claim 1 wherein the method results in an AUC inf in a range from about 25.0 ng*h/mL to about 370 ng*h/mL of cocaine in the patient.

12. The method of claim 1 wherein the method results in a reduction in pain equivalent to achieving a visual numeric rating score of 0 upon von Frey filament testing.

Assignments (4)
SECURITY INTEREST Recorded Apr 27, 2026
From: LXO IRELAND DESIGNATED ACTIVITY COMPANY
To: KROLL TRUSTEE SERVICES LIMITED, AS SECURITY AGENT
Reel/Frame 074483/0163 →
CHANGE OF NAME Recorded Dec 10, 2025
From: NODEN PHARMA DESIGNATED ACTIVITY COMPANY
To: LXO IRELAND DESIGNATED ACTIVITY COMPANY
Reel/Frame 073940/0952 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2023
From: GENUS LIFESCIENCES INC.
To: NODEN PHARMA DESIGNATED ACTIVITY COMPANY
Reel/Frame 062999/0559 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2020
From: MOSHAL, JEFFREY M.; LIBMAN, MICHAEL
To: GENUS LIFESCIENCES INC.
Reel/Frame 053484/0664 →
Continuity (5)
Continuation 16174567 · Oct 30, 2018
Continuation 15935776 · Mar 26, 2018
Continuation 15849575 · Dec 20, 2017
Continuation 15470133 · Mar 27, 2017
Continuation 15427011 · Feb 7, 2017
Cited By (1)
US 12,508,256